These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 34462985)

  • 1. Development of neuroactive steroids for the treatment of postpartum depression.
    Gunduz-Bruce H; Takahashi K; Huang MY
    J Neuroendocrinol; 2022 Feb; 34(2):e13019. PubMed ID: 34462985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [GABAergic approach of postpartum depression: A translational review of literature].
    Verbe J; Dubertret C; El-Hage W; Bonnet-Brilhault F; Duriez P
    Encephale; 2020 Apr; 46(2):123-134. PubMed ID: 31767256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder.
    Cutler AJ; Mattingly GW; Maletic V
    Transl Psychiatry; 2023 Jun; 13(1):228. PubMed ID: 37365161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy.
    Reddy DS; Mbilinyi RH; Estes E
    Psychopharmacology (Berl); 2023 Sep; 240(9):1841-1863. PubMed ID: 37566239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA
    Sharma R; Bansal P; Saini L; Sharma N; Dhingra R
    Pharmacol Biochem Behav; 2024 May; 238():173734. PubMed ID: 38387651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
    Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
    JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA
    Althaus AL; Ackley MA; Belfort GM; Gee SM; Dai J; Nguyen DP; Kazdoba TM; Modgil A; Davies PA; Moss SJ; Salituro FG; Hoffmann E; Hammond RS; Robichaud AJ; Quirk MC; Doherty JJ
    Neuropharmacology; 2020 Dec; 181():108333. PubMed ID: 32976892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating brexanolone for the treatment of postpartum depression.
    Payne JL
    Expert Opin Pharmacother; 2021 Jun; 22(8):959-964. PubMed ID: 33645386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.
    Frieder A; Fersh M; Hainline R; Deligiannidis KM
    CNS Drugs; 2019 Mar; 33(3):265-282. PubMed ID: 30790145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
    Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options.
    Rupprecht R; Pradhan AK; Kufner M; Brunner LM; Nothdurfter C; Wein S; Schwarzbach J; Puig X; Rupprecht C; Rammes G
    Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1477-1487. PubMed ID: 36574032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurosteroid replacement therapy for catamenial epilepsy, postpartum depression and neuroendocrine disorders in women.
    Reddy DS
    J Neuroendocrinol; 2022 Feb; 34(2):e13028. PubMed ID: 34506047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroactive steroids - new possibilities in the treatment of postpartum depression.
    Žigová L; Massarová P; Vranecová K; Hrubá O; Adamičková A; Gažová A
    Ceska Slov Farm; 2022; 71(4):142-150. PubMed ID: 36208918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on approved and emerging drugs for the treatment of postpartum depression.
    Çulcu EA; Demiryürek Ş; Demiryürek AT
    Ideggyogy Sz; 2024 Jul; 77(7-8):227-235. PubMed ID: 39082257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allopregnanolone in postpartum depression: Role in pathophysiology and treatment.
    Meltzer-Brody S; Kanes SJ
    Neurobiol Stress; 2020 May; 12():100212. PubMed ID: 32435663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zuranolone - synthetic neurosteroid in treatment of mental disorders: narrative review.
    Marecki R; Kałuska J; Kolanek A; Hakało D; Waszkiewicz N
    Front Psychiatry; 2023; 14():1298359. PubMed ID: 38116383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroactive Steroids and GABAergic Involvement in the Neuroendocrine Dysfunction Associated With Major Depressive Disorder and Postpartum Depression.
    Maguire J
    Front Cell Neurosci; 2019; 13():83. PubMed ID: 30906252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.
    Zou J; Yang L; Yang G; Gao J
    Psychiatry Res; 2023 Oct; 328():115450. PubMed ID: 37683318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brexanolone, a GABA
    Edinoff AN; Odisho AS; Lewis K; Kaskas A; Hunt G; Cornett EM; Kaye AD; Kaye A; Morgan J; Barrilleaux PS; Lewis D; Viswanath O; Urits I
    Front Psychiatry; 2021; 12():699740. PubMed ID: 34594247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripartum neuroactive steroid and γ-aminobutyric acid profiles in women at-risk for postpartum depression.
    Deligiannidis KM; Kroll-Desrosiers AR; Mo S; Nguyen HP; Svenson A; Jaitly N; Hall JE; Barton BA; Rothschild AJ; Shaffer SA
    Psychoneuroendocrinology; 2016 Aug; 70():98-107. PubMed ID: 27209438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.